Journal
AMERICAN JOURNAL OF MEDICAL GENETICS PART A
Volume 173, Issue 10, Pages 2605-2613Publisher
WILEY
DOI: 10.1002/ajmg.a.38350
Keywords
copy number variation; hemangioblastomas; single nucleotide variant; von Hippel-Lindau gene; whole exome sequencing
Categories
Funding
- Illinois Department of Public Health
- National Natural Science Foundation of China [81172392]
- Shanghai Committee of Science and Technology [15411951800, 15410723200]
- NIH/NIA [R01AG036042]
Ask authors/readers for more resources
Hemangioblastomas (HBs) are uncommon tumors characterized by the presence of inactivating alterations in the von Hippel-Lindau (VHL) gene in inherited cases and by infrequent somatic mutation in sporadic entities. We performed whole exome sequencing on 11 HB patients to further elucidate the genetics of HBs. A total of 270 somatic variations in 219 genes, of which there were 86 mutations in 67 genes, were found in sporadic HBs, and 184 mutations were found in 154 genes in familial HBs. C: G>T: A and T: A>C: G mutations are relatively common in most HB patients. Genes harboring the most significant mutations include PCDH9, KLHL12, DCAF4L1, and VHL in sporadic HBs, and ZNF814, DLG2, RIMS1, PNN, and MUC7 in familial HBs. The frequency of CNV varied considerably within sporadic HBs but was relatively similar within familial HBs. Five genes, including OTOGL, PLCB4, SCEL, THSD4, and WWOX, have CNVs in the six patients with sporadic HBs, and three genes, including ABCA6, CWC27, and LAMA2, have CNVs in the five patients with familial HBs. We found new genetic mutations and CNVs that might be involved in HBs; these findings highlight the complexity of the tumorigenesis of HBs and pinpoint potential therapeutic targets for the treatment of HBs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available